We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+3.35%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$957M
AUM Growth
+$1.08M
Cap. Flow
-$9.87M
Cap. Flow %
-1.03%
Top 10 Hldgs %
32.99%
Holding
140
New
9
Increased
34
Reduced
55
Closed
6

Top Buys

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$11.5M
2
SUPN icon
Supernus Pharmaceuticals
SUPN
+$9.5M
3
ONC
BeOne Medicines Ltd
ONC
+$9.49M
4
INCY icon
Incyte
INCY
+$8.91M
5
CELG
Celgene Corp
CELG
+$8.11M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$20.7M
2
GILD icon
Gilead Sciences
GILD
+$16.8M
3
ABMD
Abiomed Inc
ABMD
+$10.8M
4
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$8.6M
5
ABBV icon
AbbVie
ABBV
+$7.85M

Sector Composition

Rank Sector Weight
1 Healthcare 95.72%
2 Financials 0.41%
3 Industrials 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDCO
126
DELISTED
Medicines Co
MDCO
$488K 0.05%
17,850
-1,650
-8% -$50.8K
EVHC
127
DELISTED
Envision Healthcare Holdings Inc
EVHC
$450K 0.05%
13,026
– –
MYGN icon
128
Myriad Genetics
MYGN
$553M
$412K 0.04%
12,000
-1,000
-8% -$33.7K
AAC
129
DELISTED
AAC Holdings
AAC
$405K 0.04%
45,000
– –
SGRY icon
130
Surgery Partners
SGRY
$2.1B
$375K 0.04%
31,000
– –
ALDR
131
DELISTED
Alder Biopharmaceuticals
ALDR
$350K 0.04%
30,600
-2,400
-7% -$26.8K
ACHC icon
132
Acadia Healthcare
ACHC
$3.17B
$326K 0.03%
10,000
-21,000
-68% -$728K
HIND
133
Vyome Holdings
HIND
$15.2M
– –
0
– –
TBPH icon
134
Theravance Biopharma
TBPH
$877M
$296K 0.03%
10,628
-3,800
-26% -$112K
CLDX icon
135
Celldex Therapeutics
CLDX
$2.78B
– –
-10,667
Closed -$458K
IQV icon
136
IQVIA
IQV
$34.1B
– –
-71,170
Closed -$6.77M
ADMS
137
DELISTED
Adamas Pharmaceuticals
ADMS
– –
-24,000
Closed -$508K
MNK
138
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
– –
-229,983
Closed -$8.6M
CEMP
139
DELISTED
Cempra, Inc.
CEMP
– –
-165,000
Closed -$536K
BCR
140
DELISTED
CR Bard Inc.
BCR
– –
-22,740
Closed -$7.29M
2 3 4 5
6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2017 Portfolio in Review

As of Q4 2017, Bellevue Group held 140 positions worth $957M, up 0.11% from $956M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Bellevue Group's Q4 2017 filing shows 9 new, 34 increased, 55 reduced and 6 closed positions. Its largest new stake was Supernus Pharmaceuticals: 240,400 shares worth $9.58M. The largest sale was Amgen, an estimated $20.7M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Financials and Industrials.

  • Bellevue Group's largest Q4 2017 buy was Supernus Pharmaceuticals: 240,400 shares worth $9.58M.
  • Bellevue Group added most to DexCom in Q4 2017, an estimated $11.5M increase.
  • Bellevue Group's biggest Q4 2017 reduction was Amgen, cutting an estimated $20.7M.
  • Bellevue Group fully exited MALLINCKRODT PUBLIC LIMITED COMPANY in Q4 2017, selling an estimated $8.6M.
  • Bellevue Group's ten largest holdings make up 33% of its $957M portfolio in Q4 2017.
  • Bellevue Group opened 9 new positions and closed 6 in Q4 2017.
  • Bellevue Group's portfolio value rose 0.11% quarter-over-quarter to $957M.

Based on Bellevue Group's 13F filing for Q4 2017, filed 14 Feb 2018.